NCT04257175 2023-11-28
CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression
Sheba Medical Center
Phase 2/3 Unknown
Clinical Trials
13 trialsNCT04989335 2023-11-28
Bisantrene Combination for Resistant AML
Sheba Medical Center
Phase 2 Unknown
NCT06105658 2023-10-30
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
Anhui Provincial Hospital
Phase 2 Unknown
NCT04931992 2021-06-18
MOLAM
University Hospital, Angers
Unknown
NCT04240600 2020-09-03
HEMVEF
Hospital General de Mexico
Phase NA Unknown
NCT03978364 2019-06-07
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC
Shandong Provincial Hospital
Phase 3 Unknown
NCT03204838 2017-07-02
IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients
Hospital General de Mexico
Unknown
NCT02759822 2016-05-03
Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias
Instituto Nacional de Cancer, Brazil
Unknown
NCT02275663 2015-01-06
Azacytidine Plus FLAG for Relapsed or Refractory AML
King Fahad Medical City
Phase 2 Unknown
NCT00451711 2013-12-16
Intermittent Liposomal Amphotericin B Primary Prophylaxis
Bayside Health
Phase 2 Unknown
NCT01307241 2013-11-15
RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML
National Institute of Cancerología
Unknown
NCT00636922 2013-02-15
Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia
Bayside Health
Phase 1 Unknown
NCT01329471 2011-04-06
Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML)
Hillel Yaffe Medical Center
Unknown